CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 2, 2020 | Series C | $186M | 1 | — | — | Detail |
Mar 2, 2018 | Series C | $60M | 1 | — | — | Detail |
Jan 25, 2016 | Series B | $30M | 2 | Jolly Innovation Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | — | Series C |
Jolly Innovation Ventures | — | Series C |
JIC Genesis Fountain Healthcare Ventures | — | Series B |